ACD856
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
3
Sites
1
Countries
1
Endpoints
23
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 23 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 0 of 23 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
No normalized metric codes are available for this asset.
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT05783830Study Evaluating the Pharmacokinetics of a Single Microdose of ACD856 | ACD856 Alzheimer’s disease | Age 18-65 | Early Ph 1 | Completed | 1 | Apr 2020 | 1 | |
| NCT05077501Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856 | ACD856 Alzheimer’s disease | Age 18-65 | Ph 1 | Completed | 1 | May 2022 | - | |
| NCT05077631Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics | ACD856 Alzheimer’s disease | Age 18-65 | Ph 1 | Completed | 1 | Feb 2022 | 1 |
Showing 1-3 of 3 trials